Kestra Medical director gets 7,217 RSUs, sells 5,694 shares

KESTRA MEDICAL TECHNOLOGIES, LTD.

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Hanley Conor reported two equity transactions: a grant of 7,217 restricted stock units, each convertible into one common share and vesting on September 9, 2027 subject to continued service, and a sale of 5,694 common shares on September 8, 2026 at a weighted average price of $25.2509 per share. The sale was a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units.

Insider Trade Summary

Net Seller: 5,694 shares

Net Sell 2 txns

Insider Hanley Conor

Role Director

Sold 5,694 shs ($144K)

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F3	7,217	--	--
Sale	Common Shares F1, F2	5,694	$25.2509	$144K

Holdings After Transaction: Common Shares — 13,489 shares (Direct)

Footnotes (3)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.5100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

Key Figures

Shares sold: 5,694 shares Weighted average sale price: $25.2509 per share Sale price range: $24.9100 to $25.5100 per share +2 more

5 metrics

Shares sold 5,694 shares Common shares sold on September 8, 2026 in a sell-to-cover transaction

Weighted average sale price $25.2509 per share Average price for the 5,694 KMTS shares sold on September 8, 2026

Sale price range $24.9100 to $25.5100 per share Range of prices at which the reported 5,694 shares were sold

RSUs granted 7,217 units Restricted stock units granted on September 9, 2026, each for one common share

RSU vesting date September 9, 2027 Vesting date for the 7,217 restricted stock units, subject to continued service

Key Terms

restricted stock units, sell to cover, weighted average price

3 terms

restricted stock units financial

"The reported securities represent restricted stock units which each entitle"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"required to be sold by the reporting person pursuant to sell to cover"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KMTS director Hanley Conor report?

Hanley Conor reported a grant of 7,217 restricted stock units on September 9, 2026 and a sale of 5,694 common shares on September 8, 2026. The sale was a nondiscretionary sell-to-cover to satisfy tax withholding on vesting restricted stock units.

At what price were KMTS shares sold in the reported Form 4?

The 5,694 KMTS shares were sold at a weighted average price of $25.2509 per share. The filing states the actual sale prices ranged from $24.9100 to $25.5100, and details by price level are available from the reporting person on request.

What did the 7,217 KMTS restricted stock units granted to Hanley Conor represent?

The 7,217 restricted stock units each entitle Hanley Conor to receive one KMTS common share. According to the disclosure, these restricted stock units will vest on September 9, 2027, subject to his continued service through that date.

Why did Hanley Conor sell 5,694 KMTS shares?

The sale of 5,694 KMTS shares was a nondiscretionary “sell to cover” transaction required to satisfy tax withholding obligations connected with the vesting and settlement of restricted stock units, rather than an elective sale for portfolio reasons.

Were the reported KMTS transactions under a Rule 10b5-1 trading plan?

No. The document-level Rule 10b5-1 checkbox is unchecked, and the footnotes describing the 5,694-share sell-to-cover and the 7,217 RSU grant do not state that either transaction was executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 08:28 PM Accepted by SEC EDGAR 09/10/2026 - 08:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanley Conor

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/08/2026		S(1)		5,694	D	$25.2509(2)	6,272	D
Common Shares	09/09/2026		A		7,217(3)	A	(3)	13,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.5100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Traci S. Umberger as attorney-in-fact for Conor Hanley	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)